CD19 and acute lymphoblastic leukemia: Among hematologic malignancies, CD19-targeted CAR-T cells administered after lymphodepletion chemotherapy constitute a novel treatment for patients with refractory or relapsed B-cell malignancies, including acute lymphoblastic leukemia (ALL), CLL, and NHL.